Patent ID: 8871800

Claim:
A method of reducing Apo-B and non-HDL-cholesterol levels in a subject group, comprising administering simvastatin and an omega-3 fatty acid composition in combination therapy to a subject group, comprising: providing a subject group comprising one or more subjects which have been initially treated with 40 mg/day simvastatin for at least 8 weeks and having a baseline LDL-cholesterol level of not more than 10% above their NCEP ATP III goal after said initial treatment, with a baseline LDL-cholesterol level of at least 100 mg/dL, a baseline non-HDL-cholesterol level of at least 130 mg/dL, and a baseline triglyceride level of 200 to 499 mg/dL after said initial treatment, and reducing the Apo-B and the non-HDL-cholesterol levels of the subject group by administering to the subject group 4 g/day of the omega-3 fatty acid composition and 40 mg/day simvastatin for at least 8 weeks, wherein the omega-3 fatty acid composition comprises at least 90% by weight omega-3 fatty acids, about 40% to about 55% by weight of the fatty acid EPA, about 30% to about 60% by weight of the fatty acid DHA, and at least 80% by weight EPA and DHA as compared to the total fatty acid content of the composition, and has an EPA:DHA weight ratio of 2:1 to 1:2, and wherein the omega-3 fatty acids in the composition comprise omega-3 polyunsaturated, long-chain fatty acids, esters of omega-3 fatty acids with glycerol, esters of omega-3 fatty acids and a primary, secondary or tertiary alcohol, or a mixture thereof, and wherein the Apo-B and non-HDL-cholesterol levels of the subject group are reduced by a statistically significant amount as compared to treatment with simvastatin alone.